ABCG2 Inhibitor Therapy for PPIX-Driven EPP and XLP Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are inadequate due to the accumulation of protoporphyrin IX (PPIX) in red blood cells and liver, exacerbated by drugs and toxins, leading to phototoxicity and hepatotoxicity.
Innovation Solution
Therapeutic agents that inhibit ABCG2 activity, such as antibodies, peptides, RNAi, or CRISPR/Cas9 systems, are administered to reduce PPIX efflux from red blood cells and hepatocytes, thereby mitigating phototoxicity and hepatotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If ABCG2 activity is inhibited to reduce PPIX efflux from red blood cells and hepatocytes, then phototoxicity and hepatotoxicity are mitigated, but PPIX accumulation in these tissues increases
Solution Approach 1:
The patent applies the principle of converting harm into benefit by utilizing the harmful accumulation of PPIX in tissues as a therapeutic mechanism. By inhibiting ABCG2 efflux pumps, the patent intentionally allows PPIX to accumulate in red blood cells and hepatocytes, where it then exerts its therapeutic effect by reducing phototoxicity and hepatotoxicity through mechanisms that are not fully detailed but are implied to be protective. This transforms the traditionally harmful substance accumulation into a beneficial therapeutic outcome.
2Quantity of substance
If PPIX is allowed to accumulate in red blood cells and liver, then current treatments are inadequate, but phototoxicity and hepatotoxicity are exacerbated
Solution Approach 1:
The patent applies inversion by reversing the conventional approach to PPIX management. Instead of attempting to reduce or eliminate PPIX accumulation as current treatments do, the patent intentionally promotes and maintains PPIX accumulation in red blood cells and hepatocytes through ABCG2 inhibition. This inverted strategy transforms the pathological accumulation into a therapeutic state, suggesting that the presence of PPIX in these specific tissues, when maintained through ABCG2 inhibition, provides protective effects against phototoxicity and hepatotoxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibition of ABCG2 activity decreases PPIX distribution to the skin and liver, reducing phototoxicity and hepatotoxicity, and facilitating the metabolism and excretion of PPIX, thus providing effective treatment for EPP and XLP.
Implementation Method 1
ABCG2 is an efflux pump that transports drugs and toxins from the intracellular space to plasma and/or bile
Implementation Method 2
When EPP patients are exposed to light, PPIX gets excited and releases its energy to oxygen that can produce free radicals and result in skin damage
Data Source
AI summary
Disclosed are novel compositions and methods of using the same for the treatment of Erythropoiefic protoporphyria (EPP) and X-linked protoporphyria (XLP). Disclosed are methods and compositions related to treating Erythropoietic protoporphyria and X-linked protoporphyria. Also described are therapeutic agents that can inhibit ABCG2. For example, provided herein are therapeutic agents defined by Formula I.